Immunohistochemical expression of mitochondrial membrane complexes (MMCs) I, III, IV and V in malignant and benign periampullary epithelium: A potential target for drug therapy of periampullary cancer?

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Aloysius, Mark M ^a   Zaitoun, Abed M ^a   Bates, Timothy E ^b   Ilyas, Mohammad ^a   Constantin Teodosiu, Dumitru ^c   Rowlands, Brian J ^a   Lobo, Dileep N ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b BioCity Nottingham   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME C OXIDASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PANCREAS RESECTION; PANCREATITIS; PERIAMPULLARY CANCER; RETROSPECTIVE STUDY; TISSUE MICROARRAY; CELL PROLIFERATION; DRUG EFFECT; EPITHELIUM; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; MITOCHONDRION; OXIDATIVE STRESS; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOCHONDRIA; NEOPLASM METASTASIS; OXIDATIVE STRESS; PANCREAS; PANCREATIC NEOPLASMS; PANCREATITIS; PHOSPHORYLATION; RETROSPECTIVE STUDIES;

EID: 77950530345     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-80     Document Type: Article

References (27)

1. Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003, 112:481-490. 10.1016/S0092-8674(03)00116-8, 12600312.
2. D'Alessandro R, Roselli M, Ferroni P, Mariotti S, Spila A, Aloe S, Carone MD, Abbolito MR, Carlini S, Perri P, et al. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. Breast Cancer Res Treat 2001, 68:9-19. 10.1023/A:1017903724176, 11678313.
3. Dias N, Bailly C. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol 2005, 70:1-12. 10.1016/j.bcp.2005.03.021, 15907809.
4. Neuzil J, Dyason JC, Freeman R, Dong LF, Prochazka L, Wang XF, Scheffler I, Ralph SJ. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J Bioenerg Biomembr 2007, 39:65-72. 10.1007/s10863-006-9060-z, 17294131.
5. Neuzil J, Wang XF, Dong LF, Low P, Ralph SJ. Molecular mechanism of 'mitocan'-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Lett 2006, 580:5125-5129. 10.1016/j.febslet.2006.05.072, 16979626.
6. Brenner C, Kroemer G. Apoptosis. Mitochondria--the death signal integrators. Science 2000, 289:1150-1151. 10.1126/science.289.5482.1150, 10970229.
7. Galluzzi L, Larochette N, Zamzami N, Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830. 10.1038/sj.onc.1209598, 16892093.
8. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998, 281:1309-1312. 10.1126/science.281.5381.1309, 9721092.
9. Don AS, Hogg PJ. Mitochondria as cancer drug targets. Trends Mol Med 2004, 10:372-378. 10.1016/j.molmed.2004.06.005, 15310457.
10. Fantin VR, Leder P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006, 25:4787-4797. 10.1038/sj.onc.1209599, 16892091.
11. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 2007, 293:C12-21. 10.1152/ajpcell.00314.2006, 17475665.
12. Daley E, Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ, Bates TE. Chlorimipramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun 2005, 328:623-632. 10.1016/j.bbrc.2005.01.028, 15694394.
13. Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, et al. Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Biochem Biophys Res Commun 2007, 364:131-137. 10.1016/j.bbrc.2007.09.107, 17931597.
14. Athanasiou A, Smith PA, Vakilpour S, Kumaran NM, Turner AE, Bagiokou D, Layfield R, Ray DE, Westwell AD, Alexander SP, et al. Vanilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Biochem Biophys Res Commun 2007, 354:50-55. 10.1016/j.bbrc.2006.12.179, 17214968.
15. Dong LF, Freeman R, Liu J, Zobalova R, Marin-Hernandez A, Stantic M, Rohlena J, Valis K, Rodriguez-Enriquez S, Butcher B, et al. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin Cancer Res 2009, 15:1593-1600. 10.1158/1078-0432.CCR-08-2439, 19223492.
16. Aloysius MM, Zaitoun AM, Bates TE, Albasri A, Ilyas M, Rowlands BJ, Lobo DN. Complete absence of M2-pyruvate kinase expression in benign pancreatic ductal epithelium and pancreaticobiliary and duodenal neoplasia. BMC Cancer 2009, 9:327. 10.1186/1471-2407-9-327, 2749871, 19754967.
17. Friedrichs K, Gluba S, Eidtmann H, Jonat W. Overexpression of p53 and prognosis in breast cancer. Cancer 1993, 72:3641-3647. 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8, 8252480.
18. Imai Y, Sasaki T, Fujibayashi T. Volume-corrected mitotic index as a prognostic factor in oral squamous cell carcinomas. Oral Oncol 2001, 37:72-76. 10.1016/S1368-8375(00)00061-0, 11120486.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
20. Guzy RD, Hoyos B, Robin E, Chen H, Liu L, Mansfield KD, Simon MC, Hammerling U, Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell Metab 2005, 1:401-408. 10.1016/j.cmet.2005.05.001, 16054089.
21. Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol 2006, 91:807-819. 10.1113/expphysiol.2006.033506, 16857720.
22. Powell CS, Jackson RM. Mitochondrial complex I, aconitase, and succinate dehydrogenase during hypoxia-reoxygenation: modulation of enzyme activities by MnSOD. Am J Physiol Lung Cell Mol Physiol 2003, 285:L189-198.
23. Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007, 56:1134-1152. 10.1136/gut.2006.113068, 17625148.
24. Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ 2004, 329:668-673. 10.1136/bmj.329.7467.668, 517650, 15374918.
25. Schneider G, Siveke JT, Eckel F, Schmid RM. Pancreatic cancer: basic and clinical aspects. Gastroenterology 2005, 128:1606-1625. 10.1053/j.gastro.2005.04.001, 15887154.
26. Cardoso CM, Custodio JB, Almeida LM, Moreno AJ. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol 2001, 176:145-152. 10.1006/taap.2001.9265, 11714246.
27. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005, 5:857-866. 10.1038/nrc1737, 16327764.